- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01445561
Ultra Low Dose Interleukin-2 in Healthy Volunteers
The Safety and the Tolerability of Ultra Low Dose Interleukin-2 in Healthy Volunteers
Background:
- Interleukin-2 is a drug that can help stimulate the body s response to inflammation. High dose interleukin-2 has been used to treat different types of cancer and immune system disorders. However, it can cause frequent and often serious side effects at the doses currently used for treatment. Very low dose interleukin-2 (700 folds less than regular dose) was previously tested in cancer patients and stem cell transplant recipients. The study observed important immune changes and minimal side effects in those patients. Researchers want to test the healthy immune system's responses to very low doses of interleukin-2 to better understand how the drug works.
Objectives:
- To study the effects of very low doses of interleukin-2 on healthy volunteers.
Eligibility:
- Healthy volunteers at least 18 years of age.
Design:
- Participants will be screened with a medical history and physical exam. They will also have blood and urine samples.
- Participants will receive one of two possible very low doses of interleukin-2 every day for 5 days.
- Blood samples will be taken twice before the first dose, 1 day after the first dose, and before the next three doses. Followup blood samples will be taken on Days 7, 14, and 28 after the first dose.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
- Healthy volunteers confirmed by brief history and physical examination and blood work through the CHI screening protocol
- Males or females ages 18 years or older
EXCLUSION CRITERIA:
- History of inflammatory or autoimmune disease
- History of inflammatory or autoimmune disease in first degree relatives
- History of malignancies
- Recipients of hematopoietic stem cell transplant or solid organ transplant
- History of seizures
- Positive HIV, hepatitis B surface antigen or hepatitis C antibody
- History or clinical signs of cardiac disease including coronary artery disease, cardiac arrhythmia, congestive heart failure
- History or clinical signs of of pulmonary disease including obstructive lung disease and asthma
- Active infections requiring systemic antibiotic therapy or anti-viral therapy
- History of systemic fungal or mycobacterial infections
- Use of immune modifying medications, i.e.- non steroidal anti-inflammatory drugs (aspirin, ibuprofen, naproxen, celecoxib, ketrolac), steroid (prednisone, dexamethasone, hydrocortisone), chemotherapy (cisplatin, dacarbazine, interferon alpha, tamoxifen)
- Persons who are alcoholic or abusers of illicit drugs
- Female subjects who are or may be pregnant or lactating
- Psychiatric diagnoses or symptoms, to include hypomania, bipolar disorder, major depression, or dysthymia
- Abnormal or marginal peripheral blood count that in the opinion of the PI will cause Hemoglobin and Hematocrit levels to drop as a result of participation in this study
- Liver function tests above the normal laboratory reference range
- Renal function test above the normal laboratory reference range
- Contraindication to interleukin-2 (i.e. hypersensitivity to IL- 2 products, active coronary artery disease, patients with organ allograft)
- Recent recipient of any type of vaccination (i.e. rotavirus vaccine, BCG, influenza virus vaccine, rubella virus vaccine, mumps virus vaccine, measles vaccine, poliovirus vaccine, smallpox vaccine, typhoid vaccine, varicella virus vaccine, yellow fever vaccine) in the 4 weeks preceding and during active study participation
- Body mass index greater than 35
- Inability to comprehend the investigational nature of the study or provide informed consent
- Diabetes mellitus or fasting blood glucose of > 100 mg/dL.
- Any drugs or supplements that interfere with blood clotting such as Vit.E, NSAIDS, Warfarin (Coumadin), ticlopidine (Ticlid), clopidogrel (Plavix)
- Use of iodinated contrast media in the 4 weeks preceding and during active study participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
100,000 international units/m2 SQ daily for 5 days
|
100,000 International Units/m2 SQ daily for 5 days
|
Experimental: 2
200,000 international units/m2 SQ daily for 5 days
|
100,000 International Units/m2 SQ daily for 5 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of ultra low dose IL-2. TRSAE rate of no more than 5% would allow us to proceed with future studies.
Time Frame: 28 days
|
To determine the safety and the tolerability of ultra low dose (physiologic dose) interleukin-2 in healthy volunteers
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Human immune response (immunome) to ultra low dose IL-2 based on research lab assessments
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Chen Zhao, M.D., National Heart, Lung, and Blood Institute (NHLBI)
Publications and helpful links
General Publications
- Smith KA. Interleukin-2: inception, impact, and implications. Science. 1988 May 27;240(4856):1169-76. doi: 10.1126/science.3131876.
- Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976 Sep 10;193(4257):1007-8. doi: 10.1126/science.181845.
- Macdonald D, Jiang YZ, Gordon AA, Mahendra P, Oskam R, Palmer PA, Franks CR, Barrett AJ. Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study. Leuk Res. 1990;14(11-12):967-73. doi: 10.1016/0145-2126(90)90109-m.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 110268
- 11-H-0268
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Diseases
-
St. Jude Children's Research HospitalRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
University of Colorado, DenverNot yet recruitingHematologic Malignancy | Pediatric Patients | Other Hematologic ConditionUnited States
-
Epizyme, Inc.WithdrawnRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina
-
Innovent Biologics (Suzhou) Co. Ltd.Recruiting
-
Massachusetts General HospitalRecruiting
-
Fondazione EMN Italy OnlusCompletedHEMATOLOGIC MALIGNANCIESItaly
-
Center for International Blood and Marrow Transplant...National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedHematologic MalignancyUnited States
-
Rigshospitalet, DenmarkNovo Nordisk A/SCompletedHematologic MalignancyDenmark
-
SecuraBioCompletedHematologic MalignancyUnited States, Italy
Clinical Trials on Interleukin-2 (100,00 IU/m(2) SQ)
-
Astellas Pharma Global Development, Inc.CompletedCLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction | CLDN18.2-positive Adenocarcinoma of Esophagus | CLDN18.2-positive Gastric AdenocarcinomaGermany, Latvia
-
CicloMed LLCCmed Clinical ServicesCompletedAdvanced Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedMyelodysplastic Syndromes | Leukemia, Myeloid, AcuteJapan, Taiwan, Korea, Republic of
-
R-PharmTerminated
-
Assistance Publique - Hôpitaux de ParisShireRecruitingAcute Lymphoblastic LeukemiaFrance
-
Assistance Publique - Hôpitaux de ParisCompleted
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedAdvanced Solid TumorUnited States
-
Eisai Inc.CompletedSoft Tissue SarcomaUnited States, France, United Kingdom, Germany, Spain, Belgium, Argentina, Israel, Poland, Romania, Korea, Republic of, Canada, Netherlands, Australia, New Zealand, Singapore, Brazil, Russian Federation, Austria, Thailand, Italy, ... and more
-
University of Michigan Rogel Cancer CenterUniversity of MichiganTerminated
-
Loma Linda UniversityWithdrawnMelanoma | Metastatic Kidney CancerUnited States